Mordmüller, Benjamin
Surat, Güzin
Lagler, Heimo
Chakravarty, Sumana
Ishizuka, Andrew S.
Lalremruata, Albert
Gmeiner, Markus
Campo, Joseph J.
Esen, Meral
Ruben, Adam J.
Held, Jana
Calle, Carlos Lamsfus
Mengue, Juliana B.
Gebru, Tamirat
Ibáñez, Javier
Sulyok, Mihály
James, Eric R.
Billingsley, Peter F.
Natasha, KC
Manoj, Anita
Murshedkar, Tooba
Gunasekera, Anusha
Eappen, Abraham G.
Li, Tao
Stafford, Richard E.
Li, Minglin
Felgner, Phil L.
Seder, Robert A.
Richie, Thomas L.
Sim, B. Kim Lee
Hoffman, Stephen L.
Kremsner, Peter G.
Article History
Received: 25 June 2016
Accepted: 14 December 2016
First Online: 15 February 2017
Competing interests
: S.C., A.J.R., E.R.J., P.F.B., N.K, A.M., T.M., A.G., A.G.E., T.L., R.E.S, M.L., T.L.R., B.K.L.S. and S.L.H. are salaried employees of Sanaria Inc., the developer and owner of PfSPZ Challenge and the sponsor of the clinical trial. In addition, S.L.H. and B.K.L.S. have a financial interest in Sanaria Inc. J.J.C. is an Antigen Discovery Employee. P.L.F. owns stock and is a board member at Antigen Discovery, Inc. All other authors declare no conflicts of interest.